Literature DB >> 1871120

Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity.

A Ashkenazi1, D H Smith, S A Marsters, L Riddle, T J Gregory, D D Ho, D J Capon.   

Abstract

The infection of human cells by laboratory strains of human immunodeficiency virus type 1 (HIV-1) can be blocked readily in vitro by recombinant soluble CD4 and CD4-immunoglobulin hybrid molecules. In contrast, infection by primary isolates of HIV-1 is much less sensitive to blocking in vitro by soluble CD4-based molecules. To investigate the molecular basis for this difference between HIV-1 strains, we isolated the gp120-encoding genes from several CD4-resistant and CD4-sensitive HIV-1 strains and characterized the CD4-binding properties of their recombinant gp120 (rgp120) products. Extensive amino acid sequence variation was found between the gp120 genes of CD4-resistant and CD4-sensitive HIV-1 isolates. However, the CD4-binding affinities of rgp120 from strains with markedly different CD4 sensitivities were essentially the same, and only small differences were observed in the kinetics of CD4 binding. These results suggest that the lower sensitivity of primary HIV-1 isolates to neutralization by CD4-based molecules is not due to lower binding affinity between soluble CD4 and free gp120.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1871120      PMCID: PMC52232          DOI: 10.1073/pnas.88.16.7056

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

Review 1.  CD4: collaborator in immune recognition and HIV infection.

Authors:  E Robey; R Axel
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

2.  Designing CD4 immunoadhesins for AIDS therapy.

Authors:  D J Capon; S M Chamow; J Mordenti; S A Marsters; T Gregory; H Mitsuya; R A Byrn; C Lucas; F M Wurm; J E Groopman
Journal:  Nature       Date:  1989-02-09       Impact factor: 49.962

3.  CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle.

Authors:  P L Nara; K M Hwang; D M Rausch; J D Lifson; L E Eiden
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis.

Authors:  A Ashkenazi; L G Presta; S A Marsters; T R Camerato; K A Rosenthal; B M Fendly; D J Capon
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.

Authors:  C K Leonard; M W Spellman; L Riddle; R J Harris; J N Thomas; T J Gregory
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

7.  Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen.

Authors:  D H Smith; R A Byrn; S A Marsters; T Gregory; J E Groopman; D J Capon
Journal:  Science       Date:  1987-12-18       Impact factor: 47.728

8.  A soluble form of CD4 (T4) protein inhibits AIDS virus infection.

Authors:  K C Deen; J S McDougal; R Inacker; G Folena-Wasserman; J Arthos; J Rosenberg; P J Maddon; R Axel; R W Sweet
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

9.  Biological properties of a CD4 immunoadhesin.

Authors:  R A Byrn; J Mordenti; C Lucas; D Smith; S A Marsters; J S Johnson; P Cossum; S M Chamow; F M Wurm; T Gregory; J E Groopman; D J Capon
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

10.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

Authors:  Y Koyanagi; S Miles; R T Mitsuyasu; J E Merrill; H V Vinters; I S Chen
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

View more
  44 in total

1.  Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.

Authors:  A L Hammond; J Lewis; J May; J Albert; P Balfe; J A McKeating
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange.

Authors:  Nichole Cerutti; Barry V Mendelow; Grant B Napier; Maria A Papathanasopoulos; Mark Killick; Makobetsa Khati; Wendy Stevens; Alexio Capovilla
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

3.  Simple assay to screen for inhibitors of interaction between the human immunodeficiency virus envelope glycoprotein and its cellular receptor, CD4.

Authors:  V Chams; T Idziorek; P J Maddon; D Klatzmann
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

4.  Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.

Authors:  Jonathan Toma; Steven P Weinheimer; Eric Stawiski; Jeannette M Whitcomb; Stanley T Lewis; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

5.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.

Authors:  W A O'Brien; S H Mao; Y Cao; J P Moore
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

Authors:  P J Klasse; J P Moore
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies.

Authors:  J L Spouge
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

9.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Authors:  L S Sawyer; M T Wrin; L Crawford-Miksza; B Potts; Y Wu; P A Weber; R D Alfonso; C V Hanson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules.

Authors:  M C Gauduin; G P Allaway; P J Maddon; C F Barbas; D R Burton; R A Koup
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.